3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
37
Neoplasms
30
Colorectal Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Neoplasm Metastasis
5
Rectal Neoplasms
3
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colonic Neoplasms
3
Breast Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oligodendroglioma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Cholangiocarcinoma
2
Brain Neoplasms
2
Astrocytoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Skin Neoplasms
1
Interventions
Gemcitabine
23
Capecitabine
17
Cisplatin
11
Oxaliplatin
10
Fluorouracil
9
Leucovorin
8
Irinotecan
7
Erlotinib Hydrochloride
6
pembrolizumab
5
Radiotherapy
5
Sorafenib
4
Interleukin-12 Subunit p35
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
regorafenib
2
dehydroftorafur
2
Watchful Waiting
2
Trastuzumab
2
Pancreaticoduodenectomy
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Long-Term Synaptic Depression
2
Lapatinib
2
Filgrastim
2
Epirubicin
2
Drug Therapy
2
Dihematoporphyrin Ether
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bile Duct Neoplasms
×
trametinib
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts